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Statement of Translational Relevance 
Molecularly targeted agents have had meaningful efficacy as single agents in multiple tumor types, but 
have not resulted in durable benefit due to resistance coming often from increased feedback signaling. 
We previously demonstrated that combination targeted therapy of vascular endothelial growth factor 
(VEGF) signaling by signal transduction inhibitors inhibiting at the receptor level and downstream using 
Mitogen-activated protein kinase kinase (MEK) inhibition was more effective than either drug alone in 
preclinical models of differentiated thyroid cancer (DTC).  We report a phase I clinical trial of VEGF 
receptor inhibitor pazopanib with MEK inhibitor trametinib with an expansion in DTC showing activity 
of the combination, with potential increased benefit in NRAS-mutated DTC.  Our results support the 
hypothesis that combination targeted therapy with pazopanib and trametinib should be further explored 
in this molecular subset of DTC.  
Abstract 
Purpose: Differentiated thyroid cancer (DTC) responds to vascular endothelial growth factor (VEGF) 
receptors inhibitors. VEGF signals through RAS/RAF/MEK signaling. We evaluated the safety and 
efficacy of VEGF receptor inhibitor pazopanib and MEK inhibitor trametinib in advanced solid tumors 
and DTC. 
Experimental Design: Advanced solid tumor patients were enrolled in a phase I, multi-center trial with 
a DTC expansion cohort. Patients received pazopanib 400-800 mg and trametinib 1-2 mg daily. Efficacy 
in the expansion cohort was assessed with objective response (OR) at six months of treatment. 
Results: Twenty-six patients were enrolled in 5 dose levels. Maximum tolerated dose was not reached; 
the recommended phase II dose was pazopanib 800 mg po and trametinib 2 mg po qd.  There was one 
dose limiting toxicity on dose level 1 with grade 3 fatigue and muscle weakness. Common grade 3 
adverse events were elevated transaminases(19%), diarrhea(15%), hypertension(12%), and fatigue(8%). 
Thirteen patients were enrolled in the DTC cohort; OR was 33% (95% CI: 9.9, 65.1%) and median 
progression-free survival was 10.7 months. The cohort was terminated after planned interim analysis 
suggested insufficiently increased activity against the historical control of pazopanib alone.  Reduction 
in tumor diameter negatively correlated with p-ERK change in tumor (Spearman’s rho = -0.71; p = 
0.05).  NRAS mutation was associated with response (Fisher’s Exact p=0.008). 
Conclusions: Pazopanib+trametinib was tolerable at full single-agent doses with clinical activity in 
DTC but did not achieve the pre-specified response rate target.   
Introduction 
The vascular endothelial growth factor (VEGF) pathway is an important signaling cascade 
responsible for angiogenesis, with secondary effects that include increasing proliferation and metastasis 
of many cancers including differentiated thyroid cancer [1-3]. VEGF binds to its ligand receptor, VEGF- 
receptors (R) 1-3, which then activates a downstream signaling cascade leading to pro-survival signaling 
and transcription of genes involved in angiogenesis.  Like many receptor tyrosine kinases, VEGFR1-3 
can activate major pro-survival circuits including AKT/PI3 Kinase signaling as well as well as RAS 
signaling. The RAF/MEK/ERK signaling pathway is involved in the regulation of normal cell 
proliferation, survival and differentiation, and this pathway is frequently aberrantly upregulated in a 
wide number of cancers including differentiated thyroid cancer (DTC) [4-5].  
DTC is a highly prevalent cancer with >600,000 patients living with the disease in the United 
States presently [6].  The mainstay of therapy for the 90% of patients found with early or locally 
advanced disease is surgery and radioiodine therapy [7-8].  Mutations in BRAF and RAS genes, along 
with re-arrangements in RET, TRK and ALK genes and others have been found in the majority (70%) of 
patients [9].  Two approved therapies for advanced, radioiodine-refractory DTC, lenvatinib and 
sorafenib, are multikinase inhibitors targeting VEGFR2 in addition to other kinases [10-11].  Pazopanib 
is an orally available multikinase inhibitor of VEGFR, platelet-derived growth factor (PDGF) receptor, 
KIT, fibroblast growth factor (FGF) receptor, and RAF which is approved for advanced renal cell 
carcinoma and advanced refractory soft tissue sarcoma [12-13].  Phase II clinical trials of pazopanib in 
DTC have also shown activity, with 49 percent of patients having RECIST partial responses [14-15].   
MEK inhibitors have been tested less extensively in DTC.  Selumetinib, a selective MEK 1/2 
inhibitor, has been tested as a potential re-differentiating agent prior to radioiodine therapy in a small 
study of 20 patients, with partial responses in five patients and stable disease in three others. [16] 
Our group has previously reported that the combination of trametinib, an orally available highly 
specific inhibitor of MEK1 and MEK2, and pazopanib in thyroid cancer cell lines and xenograft models 
results in synergistic inhibition of tumor growth [17].  We hypothesized that inhibition of receptor 
tyrosine kinases VEGFR and PDGFR with the addition of MEK inhibitor trametinib could improve 
clinical benefit for DTC patients compared to pazopanib alone. We enrolled a phase I study of the 
combination of pazopanib and trametinib in all solid tumors with an expansion cohort in DTC at the 
maximum tolerated dose. 
  
Methods 
Study design 
This was an open-label, multicenter [Sidney Kimmel Comprehensive Cancer Center (SKCCC) at 
John Hopkins University (JHU) and The University of Texas MD Anderson Comprehensive Cancer 
Center (MDACC)] trial funded by the National Comprehensive Cancer Network (NCCN). Patients older 
than 18 years with advanced solid tumors that were refractory to standard of care treatment options were 
eligible for the dose-finding cohort of the study, and expansion cohorts for DTC, cholangiocarcinoma, 
and soft tissue sarcoma were subsequently enrolled at the maximum tolerated dose; here we report the 
dose-finding and DTC expansion cohorts. Subjects enrolling in the DTC expansion cohort must have 
had progressive disease within 6 months of enrolling in the study as assessed by successive imaging and 
disease that was also amenable to biopsy. Patients with DTC must have had radioiodine non-avid lesions 
or radioiodine avid lesions that have not responded to treatment with radioactive iodine (defined as ≥ 
600 millicuries (mCi), last dose at least 6 months prior to enrollment).  Other eligibility criteria included 
the presence of Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1 measurable disease, 
an Eastern Cooperative Oncology Group performance status ≤1 (or Karnofsky performance status 
≥60%) and adequate organ function as defined by absolute neutrophil count ≥1,500 cells/μL, platelet 
count ≥100,000 cells/μL, international normalized ratio ≤1.2× upper limit of normal (unless stabilized 
with anticoagulation therapy and within the recommended range for the desired level of 
anticoagulation), total bilirubin ≤1.5× upper limit of normal (or, in patients with Gilbert syndrome, total 
bilirubin >1.5× as long as direct bilirubin is normal), and serum creatinine ≤1.5× upper limit of normal 
or creatinine clearance ≥45 mL/minute and urine protein to creatinine ratio <1, or, if >1, 24-hour urine 
protein <1 g [17]. 
Evaluation and treatment 
The protocol was approved by the Institutional Review Board at both study sites, and complied 
with the International Ethical Guidelines for Biomedical Research Involving Human Subjects and the 
Declaration of Helsinki.  Eligible patients were enrolled centrally at the SKCCC at JHU. The trial was 
registered under ClinicalTrials.gov as NCT01438554. All patients provided written informed consent 
prior to enrollment. The study drugs (trametinib and pazopanib) were provided by GlaxoSmithKline 
(eventually Novartis). 
For the dose-finding cohort, patients received escalating doses of pazopanib [dose levels (DL) 
1:400 mg; DL 2: 600 mg; DL 3-5: 800 mg) and trametinib (DL 1-3: 1 mg; DL 4: 1.5 mg; DL5: 2 mg) 
orally daily every day of a 28-day cycles. Three patients would be treated per cohort in a standard 3+3 
dose escalation design. If none of the first three patients experienced a dose-limiting toxicity (DLT), 
then the next three would be treated using the next higher dose. If one of the first three had a DLT, an 
additional three patients would be enrolled at that level. If only one of six developed a DLT, then the 
dose would be escalated for the next three patients. If two or more of the six had a DLT, then the dose 
would be de-escalated to the previous dose (or dose level -1) where an additional three patients would be 
treated. The MTD was defined as the highest dose at which 0 or 1 DLTs are observed in six patients. A 
total of 6 patients would be treated at the MTD. The expansion cohort patients were treated at the MTD 
established in our initial dose-finding cohort.  
The treatment protocol allowed dose delays or reduction if patients experienced unacceptable 
side effects and adverse reactions related to study drug(s). Patients were evaluated every cycle for trial 
therapy compliance and monitoring of adverse events. The National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0 was implemented for adverse event 
monitoring. Disease assessments (computed tomography or magnetic resonance imaging) were 
performed at baseline and then every other cycle. Response was evaluated according to the RECIST, 
version 1.1 [18]. Upon progression of disease, patients were monitored for long-term adverse events and 
survival. 
Study Design 
For the dose-finding cohort, the 3+3 dose escalation design had a target toxicity of less than 
30%. For a dose level to be deemed tolerable, at least 3 patients must have been treated for 4 weeks 
without the development of a DLT prior to treating a new cohort at a higher dose level. In addition, all 
patients defining a dose level as tolerable (i.e. no DLT in cycle 1) must have received a minimum of 
75% of the intended dose for each study drug during cycle 1.   
For the expansion cohort in DTC, the primary endpoint was objective response (OR) rate by six 
months of treatment. At study entry, each patient was categorized into one of two subtype groups: 
papillary or follicular/Hurthle cell. Based on the phase II clinical trial with pazopanib, we expected that 
the papillary subtype would have a response rate of 33% and the follicular/Hurthle cell subtype would 
have a response rate of 75% [14-15]. An interim futility analysis would be conducted after response 
information was available on the first 12 patients in the expansion cohort. If the futility boundary was 
crossed, we would consider stopping the study and declaring that the combination was not showing 
sufficient activity to warrant further investigation (Supplementary methods). The stopping boundary for 
futility was a guideline, however, since the sample size was small. Specifically, the stopping rule called 
for a review if there was a 75% probability that either the response rate in the papillary subtype was less 
than 25% or the response rate in the follicular/Hurthle call subtype was less than 67% (Supplementary 
Table 1).  
 
Pharmacokinetic analysis 
Pazopanib and trametinib pharmacokinetic (PK) analyses were performed in patients in the DTC 
expansion cohort.  A full pazopanib PK profile was obtained after the first dose on Cycle 1 Day 1 
through 24 hours. In addition, pazopanib and trametinib trough concentration were obtained on Cycle 1 
Day 15 and at the time of second tumor biopsy (i.e., C2D1 ± 48 hours).  Plasma levels of total trametinib 
and pazopanib were measured using a validated LC/MS/MS methods. Briefly, trametinib was extracted 
from plasma using acetonitrile.  Chromatographic separation was achieved with a Waters X-Terra
®
 C18 
column (3.5 µm, 2.1x50mm) and isocratic elution with an acetonitrile-water-formic acid (70:30:0.1, 
v/v/v) mobile phase over a 3 min total analytical run time. An AB Sciex 5500 triple quadrupole mass 
spectrometer operated in positive electrospray ionization mode was used for the detection of trametinib. 
The assay range was 1-200 ng/mL. Briefly, pazopanib was extracted from plasma using acetonitrile.  
Chromatographic separation was achieved with a Waters X-Terra
®
 C18 column (3.5 µm, 2.1x50mm) 
and isocratic elution with an ammonium acetate-acetonitrile containing 0.1% formic acid (40:60, v/v) 
mobile phase over a 3 min total analytical run time. An AB Sciex 5500 triple quadrupole mass 
spectrometer operated in positive electrospray ionization mode was used for the detection of pazopanib. 
The assay range was 0.010-1 µg/mL, with a 1:100 dilution allowing for quantitation up to 100 µg/mL. 
Quality assurance samples were assayed with each analytic run and were within 15% of the nominal 
concentration for both assays. Individual pazopanib plasma concentrations were analyzed by standard 
non-compartmental PK methods using Phoenix WinNonlin v7.0 (Certara LP, Princeton, NJ). Maximum 
plasma concentration (Cmax) was the observed maximum value. Area under the plasma concentration 
time curve (AUC) was calculated using the linear trapezoidal rule. Steady-state trough concentrations 
(Css,min) were calculated as an average of samples obtained on Cycle 1 Day 15 and at the time of PD 
studies. 
Pharmacodynamic analysis 
Fresh tumor biopsies were obtained just prior to therapy and after 1 cycle of combination therapy in the 
DTC expansion cohort. Biopsies were processed using standard formalin fixation, paraffin embedding at 
the appropriate histology core facility for each institution and then stored at room temperature prior to 
analysis.  Immunohistochemistry with pERK was performed using anti-phospho-p44/42 MAPK 
(ERK1/2) (Thr202/Tyr204) (20G11) (4376S, Cell Signaling) rabbit monocloncal antibody. Staining was 
performed on an automated staining system (Leica-Bond, Leica Microsystem Inc., IN). Tissue sections 
(4-5µm thick) from paraffin embedded formalin fixed tissue were deparaffinized and prepared for 
staining. Sections were incubated with primary antibody (1:400 dilution) for 15 minutes followed by 
incubation with a biotin free HRP-conjugated secondary antibody. A brown signal was developed with 
DAB-detection according to the manufacturer’s instructions (Leica Microsystems Inc., IN). Staining was 
scored by pathologist (JAB) who applied a HistoScore (H-score) calculated by the percentage of tumor 
cells staining multiplied by the intensity of staining (on a scale of 0-3) [19]. Only nuclear staining was 
regarded as positive.  
Mutational analysis 
DTC cohort patients had hotspot mutational sequencing on tumor DNA from fresh biopsy specimens or 
archival tissue (if fresh biopsy tissue was not available) performed by next-generation sequencing 
(NGS) using AmpliSeq Cancer Hotspot Panel (v2) for targeted multi-gene amplification, as previously 
described [20-21]. Briefly, we used the Ion AmpliSeq Library Kit 2.0 for library preparation, Ion 
Personal Genome Machine Hi-Q OT2 Kit and Ion OneTouch 2 Instrument for emulsion PCR and 
template preparation, and the Ion Personal Genome Machine Hi-Q Sequencing Kit with the Ion 318 
Chip and Personal Genome Machine as the sequencing platform (Life Technologies). The DNA input 
ranged from 1 ng to 30 ng, as measured by Qubit 20 Fluorometer (Life Technologies). Up to 8 
specimens were barcoded using Ion Xpress Barcode Adapters (Life Technologies) for each Ion 318 
chip. One to three controls (a non-template control, a normal peripheral blood control from a male, 
and/or positive control specimens) were included in each chip. Positive controls were mixed DNA 
specimens from several cell lines with known mutations as reported previously. 
Statistical Methods: 
Proportions are reported with exact 95% binomial conﬁdence intervals.  Spearman’s correlation 
coeﬃcient was used to assess the association between percent reduction in tumor diameter by RECIST 
and change in p-ERK expression.  Binomial probabilities were compared with Chi-square or Fisher’s 
exact tests as appropriate.  Event time distributions for overall survival (OS) and progression free 
survival (PFS) were estimated with the method of Kaplan and Meier and conﬁdence intervals calculated 
using the method of Brookmeyer and Crowley.   PK parameters were summarized descriptively. Mann–
Whitney U-tests were used to assess correlations between drug exposure and toxicity.  All p-values 
reported are two-sided, and the signiﬁcance level was set at 0.05 for all analyses.   Statistical analyses 
were performed using SAS version 9.4 (SAS Institute Inc, Cary, North Carolina) and R version 3.4. 
 
  
Results 
Patients 
From November 2011 until April 2013, 26 patients with advanced solid tumors were enrolled 
[MD Anderson Cancer Center (n=14 pts) and Johns Hopkins University (n=12)]. From August 2013 
until December 2014, 13 patients with differentiated thyroid cancer were enrolled at MD Anderson 
Cancer Center (n=11 pts) and Johns Hopkins University (n=2) in this expansion cohort of pazopanib 
plus trametinib. The demographic and disease characteristics of the patients entered onto this study are 
shown in Table 1. All patients were treated according to the study protocol, and no patients remain on 
study at the time of this analysis. In the Phase I cohort of the study, 69% of patients discontinued study 
therapy for disease progression, 12% for physician or patient-initiated withdrawal, and 19% for toxicity. 
In the DTC cohort, those numbers were 62%, 31%, and 8% respectively. 
Toxicity 
Dose-escalation cohort 
 Treatment-related adverse events are detailed in Table 2. One dose-limiting toxicity of grade 3 
fatigue possibly related to study treatment was noted and this dose level was expanded; seven patients 
were enrolled due to one patient being unevaluable for toxicity due to missing doses in the first cycle of 
study drug administration. There were no further dose-limiting toxicities in the remainder of the study 
and the trial enrolled 19 more patients on dose levels 2-5. Any patient who came off study in the first 
cycle of therapy not due to treatment-related toxicity was replaced as per protocol.  
There were no treatment-related deaths and no grade 4 toxicities; the most common grade 3 
toxicities were transaminitis (19%), diarrhea (15%), and hypertension (12%). Common low-grade 
treatment related toxicities were diarrhea, rash, hypertension, nausea/vomiting, fatigue and anorexia.  
Rash was managed well with topical steroids and dosage holds as necessary; no patient was dose 
reduced due to rash. Hypertension was also well managed with anti-hypertensive therapy.   
Nine patients were dose reduced; 5 had pazopanib reduced alone, one had trametinib reduced 
alone and 3 patients had both agents reduced.  Diarrhea was the reason for dose reduction of pazopanib 
50% of the time, followed by fatigue and hypertension.  One patient was diagnosed with glaucoma and 
trametinib was reduced alone for that subject. Median dose intensity for both agents was 100% 
(pazopanib range 18%-100%; trametinib range 18%-100%).  
Differentiated thyroid cancer expansion cohort 
 Further characterizing toxicity was a secondary endpoint of the expansion cohort in DTC.  
Generally, treatment-related adverse events were similar in the DTC expansion cohort compared to the 
dose escalation cohort. Nausea/vomiting, hypertension, rash and diarrhea were still the most common 
toxicities and usually low-grade. Four patients discontinued study therapy due to non-protocol mandated 
adverse events and subsequent impact on quality of life at 1-6 cycles (median 5); low-grade diarrhea and 
fatigue were the common causes in these cases. 
Efficacy 
Dose-escalation cohort 
Twenty-five patients were evaluable for response.  Three patients had partial responses (12%) and 18 
(72%) had stable disease for a disease control rate of 84% (Figure 1).  The three patients with partial 
responses were DTC (confirmed), ovarian cancer (unconfirmed) and cholangiocarcinoma 
(unconfirmed). The only other cholangiocarcinoma patient on the study had a best response of stable 
disease. Nine patients (35%) were on study >6 cycles (DTC: 3 patients; colorectal: 2 patients; 
cholangiocarcinoma, melanoma, synovial cell sarcoma, ovarian cancer: 1 patient each).  
Differentiated thyroid cancer expansion cohort 
The primary endpoint being monitored for this expansion cohort was the six month objective 
response (OR) rate.  Of the 13 patients enrolled on study, 12 (93%) were evaluable for disease response. 
Four patients had a RECIST criteria response (33%) while 50% had stable disease (Figure 2). PFS and 
OS were secondary endpoints of the study.  The median follow-up, calculated by the reverse Kaplan 
Meier method, was 37 months.  PFS and OS are shown in Figure 3. The median progression free 
survival was 10.7 months (95% CI: 7.3, NA). The two year PFS was 25% (95% CI: 9%, 67%). Median 
survival was 29.3 months (95% CI: 18.9, NA).  
The interim analysis for this trial was performed after 12 patients were enrolled. At that time, the 
six month response information was available on the first twelve patients in the expansion cohort. The 
sample sizes in the papillary and follicular subtypes were 6 and 6 respectively and there had been 2 and 
2 ORs in the papillary and follicular subtypes. The posterior probabilities of OR less than 25% in the 
papillary and less than 67% in the follicular groups were 0.287 and 0.86 respectively. Since there was an 
86% probability that the response rate in the follicular group was less than 67%, the study was paused 
for a futility review, and ultimately halted. 
Pharmacokinetics 
Pharmacokinetic data was obtained from the 13 patients on the expansion cohort of 800 mg of 
pazopanib and 2 mg of trametinib.  For pazopanib, the Cmax, AUC0-24hr, and Css,min were 44.5±31.8 
µg/mL 952.2±680.0 µg*hr/mL, and 33.8±17.3 µg/mL, respectively.  The Css,min for trametinib was 
18.7±6.6 ng/mL.  There were also no statistically significant correlations between the worst grade of 
toxicity for the most common toxicities during cycle 1 and during treatment and pazopanib or trametinib 
exposure (p > 0.05). There were also no statistically significant correlations between the responses and 
pazopanib or trametinib exposure (p > 0.05). 
Pharmacodynamics 
The correlation of change in p-ERK expression with best RECIST response was assessed. Of the 13 
DTC cohort patients, four patients did not have tumor cells present in the post treatment biopsy, and one 
patient did not have best response assessed, leaving eight patients available for this analysis. The percent 
reduction in tumor diameter by RECIST was negatively correlated with change in p-ERK expression 
post treatment, spearmen correlation coefficient: -0.71, p = 0.05. Overall, the median change in p-ERK 
expression score was -50, with an interquartile range of -65 to -20 with 7/9 patients having reductions in 
pERK in post-treatment specimens (Figure 4). There were also no statistically significant correlations 
between the change in p-ERK expression score and pazopanib or trametinib exposure. 
Mutational Testing 
Eleven patients had tumor tissue available for sequencing, and ten of these patients were evaluable for 
response.  NRAS was present in 3 of 3 (100%) responders, and none of the 7 patients with stable disease 
or progressive disease (Fisher’s exact p = 0.008).    One responder did not have available tissue for 
sequencing.  Other mutations included BRAF V600E or TP53 (2 patients) and PIK3CA, SMO, 
CDKN2A, ALB1, and RB1 (1 patient each).  
Discussion 
Targeting pro-growth signal transduction circuits with combination molecularly targeted inhibition is a 
rational therapeutic strategy with notable successes in solid tumors, such as BRAF V600E-mutated 
metastatic melanoma and colorectal cancer [22-25].  Inhibition at the signalizing receptor level as well 
as downstream signaling proteins theoretically allows more potent inhibition of a given pathway and the 
potential to stymie compensatory feedback loops that result in resistance to molecularly targeted agents. 
We employed this strategy to target VEGF receptor signaling at the receptor level with pazopanib and 
downstream with the MEK inhibitor trametinib, both in tumor cells and endothelial cells. In preclinical 
studies in DTC, pazopanib treatment was associated with paradoxical up-regulation of p-ERK, an effect 
that could be abrogated by concurrent trametinib [17]. 
 We did see activity with this regimen in the expected tumor type of differentiated thyroid cancer, 
where we focused our primary expansion cohort, as well as cholangiocarcinoma, somewhat less 
expectedly.  Bible et al reported significant activity of single agent pazopanib in progressive radioiodine 
refractory DTC, with an overall confirmed PR rate of 49% [14-15]. The median PFS in this phase 2 
study was 360 days. Patients with follicular thyroid cancer had a 73% PR rate (8 of 11), whereas 
papillary thyroid cancer patients had PR 33% of the time (5 of 11 patients).  Mutational analysis and 
comparable pharmacodynamics studies are not available.   The current study applied a futility 
monitoring plan that would pause the study if there was a greater than 75% probability that the six 
month OR rate with the pazopanib-trametinib combination was not superior to pazopanib alone in the 
Bible study (less than 25% in the papillary subtype or less than 67% in the follicular/Hurthle cell 
subtype).  Both the PR rate and the median PFS were not superior for the combination. Small sample 
size and patient selection differences in the two studies including prior treatment history could 
potentially skew this comparison.  
MEK inhibitors have had modest activity in cholangiocarcinoma with response rates less than 
10%, and have been mostly abandoned in that histology [26-27].  In addition, a single phase II study of 
bevacizumab and erlotinib in treatment-naïve cholangiocarcinoma showed a response rate of 12%, 
suggesting the possible benefit of VEGF targeting in this rare tumor, though the relative contribution of 
VEGF inhibition vs EGFR inhibition is unknown for this non-randomized trial [28]. Our study showed 
benefit for both of the cholangiocarcinoma patients who were enrolled (one PD and one durable SD 
greater than 6 months), with the major caveat of a sample size of only 2 patients.  Indeed, we added an 
expansion cohort of cholangiocarcinoma to this trial and previously reported a 4-month PFS of 40% 
(95% CI: 24.7-64.6%) that showed a trend towards increased 4-month PFS as compared with the 
prespecified null hypothesized 4-month PFS of 25%, but this difference did not reach statistical 
significance (P=0.063) [29]. A final expansion cohort in soft tissue sarcoma did not show signs of 
compelling activity [30]. 
Our correlative studies yielded some interesting results in our exploratory analyses.  Our initial 
hypothesis was that combination pazopanib and trametinib would result in significant inhibition of the 
MAP kinase signaling pathway, and that this would correlate with clinical response.  Indeed, 7 of 9 
patients with paired tumor biopsies had inhibition of p-ERK after treatment, though without single agent 
comparators, we cannot determine if it is more or less p-ERK inhibition compared to either agent alone.  
However, inhibition of p-ERK correlated with lack of tumor response to therapy, opposite of our initial 
hypothesis.  Limitation of tissue and the small patient numbers did not allow us to understand the 
mechanism behind this exploratory finding. A possible explanation is that inhibition of the MAPK 
pathway may result in compensatory increases in other pro-survival pathways, resulting in resistance to 
this therapeutic strategy; this phenomenon was observed in a recent models of melanoma and low-grade 
glioma where MEK inhibition resulted in decreased p-ERK but resistance emerged with upregulation of 
PI3K/AKT [31-32]. A second possible explanation is that the higher levels of p-ERK are a direct effect 
of pazopanib treatment, comparable to effects observed in the cell culture and mouse models.  
Arguably, our most interesting correlative study explored the effect of common hotspot 
mutations on the potential efficacy of the pazopanib/trametinib combination in our DTC patients.  Three 
of 11 patients with available tissue had NRAS mutations, slightly higher than expected possibly due to 
the patients enrolled being more advanced cases, as RAS mutations have been suggested to represent a 
more aggressive phenotype [8, 33].  All three patients with NRAS mutations had PRs (with the final PR 
patient not having available tissue for sequencing).  With the necessary caveats regarding the low 
number of patients in this analysis, the data pose an important question regarding whether NRAS-
mutated tumors have a necessary addition to the MAPK signaling pathway making them uniquely 
sensitive to this approach.   In the phase II study of the MEK inhibitor selumetinib in DTC, patients with 
NRAS-mutated disease had increased effectiveness of therapy in comparison with BRAF-mutated 
disease, though again with small numbers [16].  Lenvatinib, another VEGFR/FGFR tyrosine kinase 
inhibitor, is approved in DTC, and a phase 2 study suggested that RAS-mutated patients had more 
benefit from lenvatinib than wild-type tumors, although this finding was not substantiated in the 
subsequent phase 3 study [34]. 
In conclusion, our data suggest that pazopanib and trametinib are tolerable and active in 
advanced solid tumor patients, particularly in DTC patients. The lack of single agent comparator arms 
do not allow for assessment of the activity of the combination over either drug alone. However, the trial 
did not meet is pre-specified threshold for activity for the follicular thyroid cancer patients, resulting in 
closing the trial for enrollment.  Future study of the combination in NRAS-mutated DTC in a larger, 
randomized trial to truly validate the findings would be meaningful to assess if this strategy has any role 
in the care of DTC patients. 
Acknowledgements: We thank the patients and their families for participating in this study. 
Figure Legends 
 
Figure 1: Best RECIST 1.1 criteria responses in dose-escalation cohort 
Twenty-five patients were available for response (24 patients represented in figure and patient 25 not 
represented due to clinical progression without imaging).  
 
Figure 2: Best RECIST 1.1 criteria responses in differentiated thyroid cohort. Eleven patients 
represented in figure, with the 12th evaluable patient not represented due to clinical progression without 
imaging. *represents new lesions resulting in RECIST criteria progression. 
 
Figure 3: Kaplan-Meier estimate of a) progression-free survival (PFS) and b) overall survival (OS) in 
differentiated thyroid cohort. The dotted lines represent 95% confidence intervals. 
 
Figure 4: Change in pERK in relation to change in tumor size.  Pre- versus post-treatment biopsies were 
assessed for pERK.  Changes in tumor size were assessed by RECIST 1.1 criteria. 
 
 
  
Table 1: Baseline Patient Characteristics 
Characteristic  Phase I  
 
(N=26) 
Thyroid 
Expansion 
(N=13) 
Age   
Median 59 60 
Range 33-82 32-74 
Sex (%)   
Male 14 (54) 7 (54) 
Female 12 (46) 6 (46) 
Race (%)   
White 20 (77) 11 (85) 
Black 2 (8) 0 
Asian 2 (8) 1 (8) 
Unknown or other 2 (8) 1 (8) 
Previous regimens   
Median 4 1 
Range 
Radiation-based therapy 
0-13 
11 
0-5 
13 
Treatment site (%)   
MD Anderson Cancer Center 14 (54) 11 (85) 
Johns Hopkins University 12 (46) 2 (15) 
ECOG performance status (%)   
0 10 (38) 2 (15) 
1 16 (62) 11 (85) 
Tumor Histology (%) 
 
  
Thyroid subtype 
     Papillary 
     Follicular       
     Hurthle cell 
     Poorly differentiated 
     Carcinoma 
Basal cell carcinoma 
Cholangiocarcinoma 
Colorectal Cancer 
Endometrial Cancer 
Maxillary sinus cancer 
Melanoma 
Merkel cell carcinoma 
Ovarian cancer 
Pancreatic ductal adenocarcinoma 
 
2 (8) 
1 (4) 
0 
1 (4) 
1 (4) 
1 (4) 
2 (8) 
2 (8) 
1 (4) 
1 (4) 
4 (15) 
1 (4) 
3 (12) 
1 (4) 
 
6 (46) 
5 (38) 
1 (8) 
1 (8) 
  
Pancreatic islet cell tumor 
Sarcoma 
Serous papillary cystadenocarcinoma  
Squamous cell base of tongue cancer 
 
 
 
1 (4) 
2 (8) 
1 (4) 
1 (4) 
 
Table 2: Treatment-related adverse events occurring two or more participants and all grade 3/4 
treatment-related adverse events (all cycles) 
Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Any Grade 
 Dose 
Escalation 
Thyroid 
Expansion 
Dose 
Escalation 
Thyroid 
Expansion 
Dose 
Escalation 
Thyroid 
Expansion 
Dose 
Escalation 
Thyroid 
Expansion 
Dose 
Escalation 
Thyroid 
Expansion 
Abdominal Pain 3 0 2 0 2 1 0 0 7 (27%) 1 (8%) 
Alopecia 1 3 0 0 0 0 0 0 1 (4%) 3 (23%) 
Anorexia 8 3 3 3 0 0 0 0 11 (42%) 6 (46%) 
Arthralgia 1 0 1 0 0 0 0 0 2 (8%) 0 
Blurry Vision / vision 
changes 
0 2 0 0 0 0 0 0 0 2 (15%) 
Constipation 3 1 1 1 0 0 0 0 4 (15%) 2 (15%) 
Cracking Skin 3 0 0 0 0 0 0 0 3 (12%) 0 
Diarrhea 10 2 8 6 4 3 0 0 22 (85%) 11 (85%) 
Dizziness 5 3 0 0 0 0 0 0 5 (19%) 3 (23%) 
Dry Eyes/Mouth 4 0 0 0 0 0 0 0 4 (15%) 0 
Dry Skin 4 2 0 0 0 0 0 0 4 (15%) 2 (15%) 
Edema 5 3 1 0 0 0 0 0 6 (23%) 3 (23%) 
Decreased EF 0 0 0 2 0 0 0 0 0 2 (15%) 
Epistaxis 3 0 0 0 0 0 0 0 3 (12%) 0 
Esophageal Ulcer 0 0 0 0 0 1 0 0 0 1 (8%) 
Fatigue 8 6 6 2 2 1 0 0 16 (62%) 9 (69%) 
Flatulence 3 0 0 0 0 0 0 0 3 (12%) 0 
Headache 4 0 1 0 1 0 0 0 6 (23%) 0 
Heartburn 2 0 1 0 0 0 0 0 3 (12%) 0 
Hypertension 4 2 7 3 3 6 0 0 14 (54%) 11 (85%) 
Hypokalemia 2 0 0 0 0 0 0 0 2 (8%) 0 
Hypomagnesemia 3 1 0 0 0 0 0 0 3 (12%) 1 (8%) 
Hypopigmentation 2 3 0 0 0 0 0 0 2 (8%) 3 (23%) 
Mucositis 4 4 0 0 0 0 0 0 4 (15%) 4 (31%) 
Muscle cramping 2 0 1 0 0 0 0 0 3 (12%) 0 
Muscle Weakness 2 0 0 0 1 0 0 0 3 (12%) 0 
Nausea/vomiting 12 7 4 5 0 0 0 0 16 (62%) 12 (92%) 
Neutropenia 1 0 0 1 0 0 0 0 1 (4%) 1 (8%) 
Palmar-Plantar 
Erythrodysesthesia 
1 1 0 1 0 0 0 0 1 (4%) 2 (15%) 
Proteinuria 0 0 1 1 1 0 0 0 2 (8%) 1 (8%) 
Pruritus 2 1 0 0 0 1 0 0 2 (8%) 2 (15%) 
Rash 13 5 4 5 1 3 0 0 18 (69%) 13 (100%) 
Taste changes 5 4 2 1 0 0 0 0 7 (27%) 5 (38%) 
Thrombocytopenia 2 1 1 1 0 0 0 0 3 (12%) 2 (15%) 
Transaminitis 3 1 0 2 5 1 0 0 8 (31%) 4 (31%) 
Weight Loss 3 2 1 0 0 1 0 0 4 (15%) 1 (8%) 
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